forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Targeted Peptide Weight Loss
Description
A new study shows the medications could have a broader effect on addiction.
Overcoming access challenges with transitional assistance The market access environment for new launch products has become progressively restrictive with payers enforcing more prior authorizations, step edits, and blocks than ever before
Eli Lillys retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1
Reduces body fat*^
Learn strategies to decide on coverage.
Discover the research linking semaglutide to LDL reduction and HDL improvement
